Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease

Figures

• 

  FIGURE 1. Dose ranges of angiotensin‐converting enzyme inhibitors (ACEIs) prescribed in Visit 1 for 144 dogs receiving an ACEI for treatment of cardiac disease. Dose frequency is indicated by column color. q24h, once daily dosing; q12h, twice daily dosing

• 

  FIGURE 2. Kaplan‐Meier curves depicting 2‐year survival from Visit 1 in a study sample of 108 dogs receiving angiotensin‐converting enzyme inhibitors (ACEIs) for treatment of cardiac disease with long‐term follow‐up data available, comparing dogs receiving high‐dose (≥0.5 mg/kg/day, gray line) vs low‐dose (<0.5 mg/kg/day, black line) ACEI (A) and dogs receiving q12h (gray line) vs q24h (black line) ACEI dosing (B). Neither ACEI dose (P = .1, A) nor dose frequency (P = .43, B) were significant predictors of 2‐year survival in the full study sample

• 

  FIGURE 3. Kaplan‐Meier curve depicting 2‐year survival from Visit 1 for the subset of 48 dogs who were in congestive heart failure at Visit 1 and had long‐term outcome data available, comparing dogs receiving high‐dose angiotensin‐converting enzyme inhibitors (ACEIs; ≥0.5 mg/kg/day, gray line) vs low‐dose (<0.5 mg/kg/day, black line). Higher ACEI dose was associated with higher probability of survival 2 years (P = .04)

• 

  FIGURE 4. Kaplan‐Meier curve depicting time from first‐onset congestive heart failure (CHF) to all‐cause mortality for the subset of 61 study dogs with survival data that experienced CHF at some point during the study period (at or after Visit 1). Dogs receiving high‐dose angiotensin‐converting enzyme inhibitors (ACEIs; ≥0.5 mg/kg/day, gray) had longer survival from first‐onset CHF compared to dogs receiving lower ACEI doses (black; P = .005)